TEVA•benzinga•
UPDATE: Teva Cuts FY22 Sales Guidance From $15.6B-$16.2B To $15.4B-$16B vs $15.97B Estimate, Reaffirms Adj. EPS Guidance $2.40-$2.60 vs $2.51 Est.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga